Absence of pharmacokinetic drug-drug interaction of pertuzumab with trastuzumab and docetaxel.
Abstract |
|
Authors | Javier Cortés, Sandra M Swain, Iveta Kudaba, Maik Hauschild, Taral Patel, Elza Grincuka, Norikazu Masuda, Virginia McNally, Graham Ross, Mike Brewster, Jean-François Marier, My My Trinh, Amit Garg, Ihsan Nijem, Jennifer Visich, Bert L Lum, José Baselga |
Journal | Anti-cancer drugs
(Anticancer Drugs)
Vol. 24
Issue 10
Pg. 1084-92
(Nov 2013)
ISSN: 1473-5741 [Electronic] England |
PMID | 23969513
(Publication Type: Clinical Trial, Phase III, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antibodies, Monoclonal, Humanized
- Taxoids
- Docetaxel
- ERBB2 protein, human
- Receptor, ErbB-2
- pertuzumab
- Trastuzumab
|
Topics |
- Antibodies, Monoclonal, Humanized
(administration & dosage, blood, pharmacokinetics, therapeutic use)
- Antineoplastic Combined Chemotherapy Protocols
(administration & dosage, blood, pharmacokinetics, therapeutic use)
- Breast Neoplasms
(blood, drug therapy, metabolism, pathology)
- Docetaxel
- Drug Administration Schedule
- Drug Interactions
- Female
- Humans
- Middle Aged
- Models, Biological
- Neoplasm Metastasis
- Receptor, ErbB-2
(metabolism)
- Taxoids
(administration & dosage, pharmacokinetics, therapeutic use)
- Trastuzumab
|
|
Join CureHunter, for free Research Interface BASIC access!
Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease.
Find out why thousands of doctors, pharma researchers and patient activists
around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!
|